Paul Bradbury/OJO Images via Getty Images Introduction Bristol Myers Squibb (NYSE:BMY) announced its Q2 2024 earnings on Thursday. My previous coverage of BMS was nearly a year ago, following Q2 2023 earnings, which inspired 52-week lows due to concerns about generic competition and patent cliffs. Revlimid, a blockbuster drug for the treatment of multiple myeloma, has seen its revenues fall since a generic version was released in early 2022. At its peak, Revlimid generated more than $10 billion per year ...

With interest rates expected to decline, high-yield dividend stocks offer attractive income potential and possible capital appreciation.Dividend investing has long been a popular strategy for generating passive income and building long-term wealth. High-yield dividend stocks, in particular, can offer attractive returns to investors seeking regular cash flow from their portfolios. These stocks typically pay out a higher percentage of their earnings as dividends compared to the broader market average.Recent e ...

JHVEPhoto/iStock Editorial via Getty Images Investment thesis Bristol-Myers Squibb (NYSE:BMY) has just recently released its Q2 earnings, which were very positively absorbed by the market as the stock delivered an 11% rally on Friday after the report went live. The company delivered a strong quarter with wide positive revenue and EPS surprises. BMY demonstrates exceptional profitability which allows the company to grow through acquisitions, boost innovation, and return cash to shareholders. The stock b ...

The pharmaceutical company is faring far better than most investors were anticipating at this point.Bristol Myers Squibb (BMY 9.94%) shareholders are certainly finishing the trading week on a high note. The drugmaker's stock is up 9.6% as of 1:14 p.m. ET, according to data from S&P Global Market Intelligence, in response to a surprisingly strong second-quarter report and subsequently raised full-year guidance.Bristol Myers Squibb is firing on all cylindersGive credit to Bristol Myers Squibb's newer drugs li ...

Bristol-Myers Squibb Company (NYSE:BMY) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Head of Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Chris Schott - JPMorg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Commission File Number 001-01136 ___________________________ BRISTOL-MYERS SQUIBB COMPANY (Exact ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday.The Dow traded up 1.60% to 40,574.53 while the NASDAQ rose 0.74% to 17,309.62. The S&P 500 also rose, gaining, 0.99% to 5,452.49.Check This Out: Jim Cramer Is ‘Mystified’ By Five Below, Predicts CrowdStrike ‘Is Going To Bottom Here’Leading and Lagging SectorsIndustrials shares jumped by 1.7% on Wednesday.In trading on Wednesday, energy shares fell by 0.3%.Top HeadlineBristol Myers Squibb & Co BMY  p ...

It’s been an eventful week in the markets. And this morning, we have arguably the most substantial numbers of all: Personal Consumption Expenditures (PCE) for June, the Fed’s preferred measure of inflation. Both headline figures came in-line with estimates: +0.1% month over month and +2.5% year over year, up +10 basis points (bps) on the former and -10 bps on the latter. Pre-market futures are jumping this morning, though this may have to do with favorable market conditions after the sell-off mid-week.Impor ...

Bristol-Myers Squibb Company (BMY) reported an adjusted earnings per share (EPS) of $2.07, which beat the Zacks Consensus Estimate of $1.64.  In the year-ago quarter, BMY posted an adjusted EPS of $1.75.Total revenues of $12.2 billion surpassed the Zacks Consensus Estimate of $11.5 billion. The top line also increased 9% from the year-ago period’s level, primarily driven by strong growth portfolio performance and an increase in Eliquis sales.BMY’s shares are trading up following the results.The company’s sh ...

Key TakeawaysBristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations.The company raised its full-year adjusted EPS guidance and now projects adjusted revenue to land in the upper end of its previously issued range.Revenue growth was driven by sales of its blood thinner Eliquis and cancer drug Opdivo. Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance. The pharmaceutical giant ...